BIOLOGIC medicines are increasingly being added to the range of tools used to manage auto-immune disorders.
Of these, the monoclonal antibody Cosentyx (secukinumab) has demonstrated efficacy in, and is indicated in Australia for the treatment of plaque psoriasis, ankylosing spondylitis, and psoriatic arthritis.
By targeting the pro-inflammatory cytokine IL-17A, Cosentyx (secukinumab) inhibits a number of cellular mechanisms associated with the development of auto-immune disorders.
To assist pharmacists in managing auto-immune disorders, Guild Learning and Development is launching an online course titled Cosentyx: A guide for community pharmacists.
This activity has been accredited for 1 hour of Group 1 CPD (or 1 CPD credit), suitable for inclusion in an individual pharmacist's CPD plan, which can be converted to 1 hour of Group 2 CPD (or 2 CPD credits) upon successful completion of relevant assessment activities.
To enrol in this course please visit www.myCPD.org.au.
Guild Learning and Development thanks Novartis for its financial support and assistance in the development of this course.
The above article was sent to subscribers in Pharmacy Daily's issue from 15 May 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 15 May 18